|Bid||25.50 x 0|
|Ask||25.62 x 0|
|Day's Range||25.01 - 25.94|
|52 Week Range||21.41 - 34.31|
|Beta (5Y Monthly)||0.13|
|PE Ratio (TTM)||25.56|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||0.36 (1.47%)|
|Ex-Dividend Date||Oct 26, 2020|
|1y Target Est||25.56|
Grifols (GRFS) to begin a study in Spain to evaluate a plasma-derived medicine that would provide immediate immunity against COVID-19.
Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex®-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
RIMOUSKI, QC, Jan. 15, 2021 /CNW Telbec/ - Canada Economic Development for Quebec Regions (CED)To support organizations in the tourism sector and prepare them for an eventual recovery, the Government of Canada will announce financial assistance in several regions across Quebec on January 18 and 19, 2021.